Halozyme Therapeutics, Inc.
HALO
Rank in Stocks
#1547
Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San... Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20). This innovative technology significantly enhances the subcutaneous (under-the-skin) administration of a diverse range of injectable medicines. This includes complex biologics such as monoclonal antibodies, various other therapeutic molecules, smaller drug compounds, and even fluids. The company's leading product, Hylenex recombinant, is an rHuPH20 formulation specifically designed to facilitate subcutaneous fluid delivery for hydration. It also plays a crucial role in improving the dispersion and absorption of other injected drugs during subcutaneous urography, and aids in the resorption of radiopaque agents. Halozyme also offers several key therapeutics leveraging its platform, including Perjeta, RITUXAN HYCELA, and MabThera SC, which are used to treat non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL). RITUXAN SC is another offering for CLL patients, while HYQVIA addresses various immunodeficiency disorders. Their development pipeline boasts numerous investigational drugs, such as Tecentriq for non-small cell lung cancer, OCREVUS for multiple sclerosis, and DARZALEX, which targets amyloidosis, smoldering myeloma, and multiple myeloma. Other pipeline candidates include nivolumab for solid tumors, ARGX-113 (a human neonatal Fc receptor), ARGX-117 for autoimmune diseases, and BMS-986179, an anti-CD-73 antibody. Halozyme maintains extensive collaborations with prominent pharmaceutical companies like F. Hoffmann-La Roche, Pfizer Inc., Janssen Biotech, Inc., AbbVie, Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Alexion Pharma Holding, ARGENX BVBA, and Horizon Therapeutics plc. They also partner with research institutions such as the National Institute of Allergy and Infectious Diseases, the Centre for the AIDS Programme of Research in South Africa, and ViiV Healthcare Limited, particularly focusing on both small and large molecule targets for the treatment and prevention of HIV. The company was established in 1998.
Share Price
$123.84
Last synced: 2026-10-20
Market Cap
$14.06B
Change (1 day)
1.09%
Change (1 year)
85.17%
Country
US
Trade Halozyme Therapeutics, Inc. (HALO)
Category
Healthcare
P/E ratio for Halozyme Therapeutics, Inc. (HALO)
P/E ratio as of October 2026 TTM: 33.19
According to Halozyme Therapeutics, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 33.19. At the end of 2023 the company had a P/E ratio of 17.32.
P/E ratio history for Halozyme Therapeutics, Inc. from 2001 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 33.19 | 143.13% |
| 2024 | 13.65 | -21.15% |
| 2023 | 17.32 | -55.05% |
| 2022 | 38.52 | 174.31% |
| 2021 | 14.04 | -68.84% |
| 2020 | 45.07 | -227.22% |
| 2019 | -35.42 | 35.59% |
| 2018 | -26.13 | -159.52% |
| 2017 | 43.89 | -459.83% |
| 2016 | -12.20 | -82.10% |
| 2015 | -68.13 | 293.44% |
| 2014 | -17.32 | -14.52% |
| 2013 | -20.26 | 45.54% |
| 2012 | -13.92 | -71.79% |
| 2011 | -49.34 | 251.50% |
| 2010 | -14.04 | 60.96% |
| 2009 | -8.72 | -5.11% |
| 2008 | -9.19 | -58.44% |
| 2007 | -22.11 | -35.28% |
| 2006 | -34.17 | 395.28% |
| 2005 | -6.90 | -19.50% |
| 2004 | -8.57 | -97.66% |
| 2003 | -366.80 | 22.46% |
| 2002 | -299.53 | 132.99% |
| 2001 | -128.56 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 28.78 | -13.28% |
US
|
|
| -28.36 | -185.45% |
US
|
|
| -24.57 | -174.02% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -8.61% |
NL
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.